a progression from non-alcoholic steatohepatitis (NASH) to non-alcoholic hepatic fibrosis.

[Claim 10] The pharmaceutical composition according to claim 1 for inhibition of a progression from non-alcoholic hepatic fibrosis to non-alcoholic hepatic cirrhosis.

[Claim 11] The pharmaceutical composition according to claim 1 for inhibition of a progression from non-alcoholic hepatic cirrhosis to liver cancer.

[Claim 12] The pharmaceutical composition according to claim 1 for inhibition of a progression from non-alcoholic steatohepatitis (NASH) to liver cancer.

[Claim 13] The pharmaceutical composition according to claim 1 wherein the pharmaceutical composition comprises as an active ingredient a daily dose of 1 to 25 mg of the compound (I) or a pharmaceutically acceptable salt thereof.

[Claim 14] The pharmaceutical composition according to claim 13 wherein the pharmaceutical composition comprises as an active ingredient a daily dose of 1 to 10 mg of the compound (I) or a pharmaceutically acceptable salt thereof.

[Claim 15] The pharmaceutical composition according to claim 14 wherein the pharmaceutical composition comprises as an active ingredient a daily dose of 2.5 to 10 mg of the compound (I) or a pharmaceutically acceptable salt thereof.

[Claim 16] The pharmaceutical composition according to claim 15 wherein the pharmaceutical composition comprises as an active ingredient a daily dose of 2.5 mg, 5 mg, or 10 mg of the compound (I) or a pharmaceutically acceptable salt thereof.

[Claim 17] The pharmaceutical composition according to claim 1 wherein the pharmaceutical composition is used in combination with one or more other therapeutic agents.

[Claim 18] The pharmaceutical composition according to claim 17 wherein said other therapeutic agent is selected from the group consisting of at least one of angiotensin converting enzyme inhibitor, angiotensin II type 1 receptor antagonist, biguanide antidiabetic agent, thiazolidine antidiabetic agent, α-glucosidase inhibitor, insulin secretion promotors, vitamins, eicosapentaenoic acid, agents for treating dyslipidemia, HMG-CoA reductase inhibitor, ursodeoxycholic acid, and agents for treating non-alcoholic steatohepatitis (NASH).

[Claim 19] The pharmaceutical composition according to claim 17 wherein at least